216 related articles for article (PubMed ID: 20856201)
1. Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer.
He X; Arslan AD; Pool MD; Ho TT; Darcy KM; Coon JS; Beck WT
Oncogene; 2011 Jan; 30(3):356-65. PubMed ID: 20856201
[TBL] [Abstract][Full Text] [Related]
2. Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20.
He X; Ee PL; Coon JS; Beck WT
Clin Cancer Res; 2004 Jul; 10(14):4652-60. PubMed ID: 15269137
[TBL] [Abstract][Full Text] [Related]
3. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
4. Sam68 is Overexpressed in Epithelial Ovarian Cancer and Promotes Tumor Cell Proliferation.
Dong L; Che H; Li M; Li X
Med Sci Monit; 2016 Sep; 22():3248-56. PubMed ID: 27623016
[TBL] [Abstract][Full Text] [Related]
5. Snail Driving Alternative Splicing of CD44 by ESRP1 Enhances Invasion and Migration in Epithelial Ovarian Cancer.
Chen L; Yao Y; Sun L; Zhou J; Miao M; Luo S; Deng G; Li J; Wang J; Tang J
Cell Physiol Biochem; 2017; 43(6):2489-2504. PubMed ID: 29131012
[TBL] [Abstract][Full Text] [Related]
6. SRp20 is a proto-oncogene critical for cell proliferation and tumor induction and maintenance.
Jia R; Li C; McCoy JP; Deng CX; Zheng ZM
Int J Biol Sci; 2010 Dec; 6(7):806-26. PubMed ID: 21179588
[TBL] [Abstract][Full Text] [Related]
7. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
8. Targeting HSF1 leads to an antitumor effect in human epithelial ovarian cancer.
Chen YF; Wang SY; Yang YH; Zheng J; Liu T; Wang L
Int J Mol Med; 2017 Jun; 39(6):1564-1570. PubMed ID: 28487934
[TBL] [Abstract][Full Text] [Related]
9. Dickkopf-4 is frequently overexpressed in epithelial ovarian carcinoma and promotes tumor invasion.
Wang S; Wei H; Zhang S
BMC Cancer; 2017 Jun; 17(1):455. PubMed ID: 28666421
[TBL] [Abstract][Full Text] [Related]
10. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
11. Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells.
Faddaoui A; Sheta R; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Gobeil S; Morin C; Ghani K; Bachvarov D
Cell Cycle; 2017 Apr; 16(7):693-706. PubMed ID: 28278050
[TBL] [Abstract][Full Text] [Related]
12. High expression of CTHRC1 promotes EMT of epithelial ovarian cancer (EOC) and is associated with poor prognosis.
Hou M; Cheng Z; Shen H; He S; Li Y; Pan Y; Feng C; Chen X; Zhang Y; Lin M; Wang L; Ke Z
Oncotarget; 2015 Nov; 6(34):35813-29. PubMed ID: 26452130
[TBL] [Abstract][Full Text] [Related]
13. EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer.
Fu Y; Chen J; Pang B; Li C; Zhao J; Shen K
Cell Biochem Biophys; 2015 Jan; 71(1):105-12. PubMed ID: 25077680
[TBL] [Abstract][Full Text] [Related]
14. Relations between GPR4 expression, microvascular density (MVD) and clinical pathological characteristics of patients with epithelial ovarian carcinoma (EOC).
Ren J; Jin W; Gao YE; Zhang Y; Zhang X; Zhao D; Ma H; Li Z; Wang J; Xiao L; Liu R; Chen Y; Qian J; Niu L; Wei H; Liu Y
Curr Pharm Des; 2014; 20(11):1904-16. PubMed ID: 23888957
[TBL] [Abstract][Full Text] [Related]
15. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
Li H; Cai Q; Godwin AK; Zhang R
Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
[TBL] [Abstract][Full Text] [Related]
16. Long Noncoding RNA CCAT2 Knockdown Suppresses Tumorous Progression by Sponging miR-424 in Epithelial Ovarian Cancer.
Hua F; Li CH; Chen XG; Liu XP
Oncol Res; 2018 Mar; 26(2):241-247. PubMed ID: 28550684
[TBL] [Abstract][Full Text] [Related]
17. Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk.
Chornokur G; Lin HY; Tyrer JP; Lawrenson K; Dennis J; Amankwah EK; Qu X; Tsai YY; Jim HS; Chen Z; Chen AY; Permuth-Wey J; Aben KK; Anton-Culver H; Antonenkova N; Bruinsma F; Bandera EV; Bean YT; Beckmann MW; Bisogna M; Bjorge L; Bogdanova N; Brinton LA; Brooks-Wilson A; Bunker CH; Butzow R; Campbell IG; Carty K; Chang-Claude J; Cook LS; Cramer DW; Cunningham JM; Cybulski C; Dansonka-Mieszkowska A; du Bois A; Despierre E; Dicks E; Doherty JA; Dörk T; Dürst M; Easton DF; Eccles DM; Edwards RP; Ekici AB; Fasching PA; Fridley BL; Gao YT; Gentry-Maharaj A; Giles GG; Glasspool R; Goodman MT; Gronwald J; Harrington P; Harter P; Hein A; Heitz F; Hildebrandt MA; Hillemanns P; Hogdall CK; Hogdall E; Hosono S; Jakubowska A; Jensen A; Ji BT; Karlan BY; Kelemen LE; Kellar M; Kiemeney LA; Krakstad C; Kjaer SK; Kupryjanczyk J; Lambrechts D; Lambrechts S; Le ND; Lee AW; Lele S; Leminen A; Lester J; Levine DA; Liang D; Lim BK; Lissowska J; Lu K; Lubinski J; Lundvall L; Massuger LF; Matsuo K; McGuire V; McLaughlin JR; McNeish I; Menon U; Milne RL; Modugno F; Moysich KB; Ness RB; Nevanlinna H; Eilber U; Odunsi K; Olson SH; Orlow I; Orsulic S; Weber RP; Paul J; Pearce CL; Pejovic T; Pelttari LM; Pike MC; Poole EM; Risch HA; Rosen B; Rossing MA; Rothstein JH; Rudolph A; Runnebaum IB; Rzepecka IK; Salvesen HB; Schernhammer E; Schwaab I; Shu XO; Shvetsov YB; Siddiqui N; Sieh W; Song H; Southey MC; Spiewankiewicz B; Sucheston L; Teo SH; Terry KL; Thompson PJ; Thomsen L; Tangen IL; Tworoger SS; van Altena AM; Vierkant RA; Vergote I; Walsh CS; Wang-Gohrke S; Wentzensen N; Whittemore AS; Wicklund KG; Wilkens LR; Wu AH; Wu X; Woo YL; Yang H; Zheng W; Ziogas A; Hasmad HN; Berchuck A; ; ; Iversen ES; Schildkraut JM; Ramus SJ; Goode EL; Monteiro AN; Gayther SA; Narod SA; Pharoah PD; Sellers TA; Phelan CM
PLoS One; 2015; 10(6):e0128106. PubMed ID: 26091520
[TBL] [Abstract][Full Text] [Related]
18. BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism.
Wang ZQ; Faddaoui A; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Guillemette C; Gobeil S; Macdonald E; Vanderhyden B; Bachvarov D
Oncotarget; 2015 Oct; 6(31):31522-43. PubMed ID: 26372729
[TBL] [Abstract][Full Text] [Related]
19. MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression.
Tang W; Jiang Y; Mu X; Xu L; Cheng W; Wang X
Cell Signal; 2014 Jul; 26(7):1420-6. PubMed ID: 24607788
[TBL] [Abstract][Full Text] [Related]
20. The lncRNA HULC functions as an oncogene by targeting ATG7 and ITGB1 in epithelial ovarian carcinoma.
Chen S; Wu DD; Sang XB; Wang LL; Zong ZH; Sun KX; Liu BL; Zhao Y
Cell Death Dis; 2017 Oct; 8(10):e3118. PubMed ID: 29022892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
